

MOLECULAR DIAGNOSTICS

SUMMIT 2015

Includes four co-located conferences:

Cancer Markers & Liquid Biopsies
Companion Diagnostics
Pathology Diagnostics
Point-of-Care Diagnostics

Keynote Speakers

Mark Curran

VP Immunology Biomarker
Janssen

Robert McCormack

Senior Director, Translational Biomarkers
Janssen Oncology

Aydogan Ozcan

Chancellor's Professor, UCLA Electrical Engineering & Bioengineering
HHMI Professor, Howard Hughes Medical Institute
Associate Director, California NanoSystems Institute
University of California, Los Angeles

Katherine Richardson

Vice President, Research & Development,
Transgenomic, Inc

JUNE 11-12, 2015 • SAN DIEGO, CA

Platinum Sponsors

trovagene
precision cancer monitoring

Media Partners

bc Biocompare
The Buyer's Guide for Life Scientists

antibodies -online.com

 Global Information, Inc.


**BENTHAM
SCIENCE**

Gold Sponsors

Esterline
LRE Medical

 **cancers**
an open access journal by Wiley

 **AllSeq**

 **pharmaceuticals**
an open access journal by Wiley

 **BioPharma
DIVE**

BIOSCREENING.COM
DRUG DISCOVERY PORTAL

SmartBrief

 **Technology
Networks.com**
Scientific Communities

BENEFITS

ABOUT

We invite you to attend the **Molecular Diagnostics Summit**, which takes place **June 11 - 12, 2015** in **San Diego, CA** at the **Hyatt Regency Mission Bay**. Join leaders from pharmaceuticals, healthcare organizations, and academia to learn about and discuss new emerging technologies, reimbursement, clinical utility, validation, applications, and what the future holds for the diagnostics areas listed below in these 4 co-located conferences:

[Cancer Markers & Liquid Biopsies](#)

[Pathology Diagnostics](#)

[Companion Diagnostics](#)

[Point-of-Care Diagnostics](#)

Sign up for a Summit Pass in order to get the most comprehensive look at the research and developments in the molecular diagnostics field.

POSTER AND ORAL PRESENTATION OPPORTUNITIES

If you are interested in participating in the Summit's poster session to showcase your work and research, please submit an abstract [here](#) and select which conference you would like to present in by **May 11, 2015**. In addition, the top two to three abstracts submitted for each individual conference will be selected to a short oral presentations as part of that conference's program. Presentation slots fill up fast so please submit your abstract ASAP.

SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind: we create intimate and highly interactive environments so that they can maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

- Sponsors/exhibitors will receive the delegate list a week before and a week after the conference.
- Exhibit space is shared between all conferences, providing sponsors/exhibitors access to delegates at all conferences. Exhibitors are located in the same room where all networking functions take place. The coffee, snack stations, breakfast, and reception all occur in this room.
- Your corporate logo will be placed on the cover page of the conference brochures, the USB proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf
Account Executive
amber.kempf@gtcbio.com

Steve Holmstrom
Account Executive
steve.holmstrom@gtcbio.com

SPONSORS

PLATINUM



Trovagene is a molecular diagnostics company providing precise, noninvasive urine and blood testing for detecting and monitoring oncogene mutations. By utilizing proprietary technology that analyzes circulating tumor DNA, Trovagene testing offers critical data that may help inform cancer treatment decisions, giving physicians and patients monitoring options beyond biopsy or imaging.

GOLD

LRE Medical GmbH, a subsidiary of Esterline Corporation, is a leading contract developer and manufacturer of IVD instrumentation for OEMs. LRE offers “One Stop Shopping” solutions for converting ideas into commercially successful products. We integrate customer assay “know-how” with our instrumentation expertise. LRE’s instruments are competitively priced, yet manufactured with superior quality!



AGENDA AT-A-GLANCE

Day 1 - Thursday, May 21, 2015

7:00 Registration & Continental Breakfast
7:55 Welcome & Opening Remarks

Cancer Markers & Liquid Biopsies

Pathology Diagnostics

Companion Diagnostics

Point-of-Care Diagnostics

KEYNOTE SESSION

Joint Session:
Reimbursement and Clinical Utility

Morning Networking & Refreshment Break

Session I
Clinical and Biological
Challenges in Cancer
Diagnosis and Prognosis

Session I
Application of Sequencing in
the Clinical Paradigm

Session I
Biomarkers in Drug
Development

Panel Discussion:
Partnerships: Pharmacies and
Manufacturers

Lunch on Your Own

Session II
Clinical Utility of Circulating
Nucleic Acids and CTCs

Session II
Multiplex Biomarker
Diagnostics and Technology

Session II
CDx: Present and Future

Session I
New and Emerging
Technologies

Session III
Isolation and
Characterization of CTCs

Panel Discussion:
Panel: Market Access for
Companion Diagnostics

Afternoon Networking & Refreshment Break

Session III
Isolation and
Characterization of CTCs
(cont.)

Session II
Multiplex Biomarker
Diagnostics and Technology
(cont.)

Session III
Companion Diagnostics
for Cancer and
Neurodegenerative Diseases

Session I
New and Emerging
Technologies

Networking Reception & Poster Session

Day 2 - Friday, May 22, 2015

Continental Breakfast

Cancer Markers & Liquid Biopsies

Pathology Diagnostics

Companion Diagnostics

Point-of-Care Diagnostics

Session IV
Validation and Application of
Cancer Specific Markers

Joint Session
Implementation of Personalized Medicine

Session II
Challenges in POC
Diagnostics

Morning Networking & Refreshment Break

Session V
Current Progress in Exosome
Application

Joint Session
Implementation of Personalized Medicine (cont.)

Session III
Integrating POC with
Centralized Care


Session IV
New Disease Areas and
Global Health

Lunch Provided by GTCbio

Conferences Conclude

All times are approximate and subject to changes without notice

KEYNOTE SPEAKERS



Informing Development and Treatment Decisions with CTCs

Robert McCormack
Janssen Oncology



Session: Clinical and Biological Challenges in Cancer Diagnosis and Prognosis

Katherine Richardson
Transgenomic

DISTINGUISHED SPEAKERS



Identifying and Overcoming Markers of Chemoresistance

Jason Baum
Merrimack Pharmaceuticals



Targeting Microtentacles on Circulating Breast Tumor Cells to Reduce Metastasis

Stuart Martin
University of Maryland School of Medicine



Exosomal Biogenesis- The Role of Exosomal Cargo

Suraj Bhat
University of California, Los Angeles



Exosomes and Liquid Biopsies: Non-Invasive Genotyping in Oncology

Vincent O'Neill
Exosome Diagnostics



Resolving Cellular and Genomic Heterogeneity in FFPE Samples Using the DEPArray Platform

Farideh Bischoff
Silicon Biosystems



Proteomic Characterization of Circulating Extracellular Vesicles Identifies CD44 as a Novel Serum Myeloma Associated Marker

Flavia Pichiorri
Ohio State University



Mass Spectrometry and the Identification and Validation of Circulating Biomarkers

Daniel Chelsky
Caprion



Molecular Profiling of Single Circulating Tumor Cells

Bernhard Polzer
Fraunhofer Institute for Toxicology and Experimental Medicine



New Technologies for Single-Cell Isolation and Analysis

Daniel Chiu
University of Washington



The Yin and Yang of ctDNA

Stefan Scherer
Novartis Pharmaceuticals Corporation



Quantifying the Evolutionary Dynamics of Tumor Growth and Progression

Christina Curtis
Stanford School of Medicine



Session: Validation and Application of Cancer Specific Markers

Anthony Shuber
Nabsys

DISTINGUISHED SPEAKERS (cont.)



Session: Validation and Application of Cancer Specific Markers

Daniel Danila
Memorial Sloan Kettering Cancer Center



Molecular Profiling of Rare Circulating Tumor Cells with Divergent Phenotypes

Steven Soper
University of North Carolina, Chapel Hill



Quantitating ctDNA Mutations from Patient Urine as an Early Pharmacodynamic Biomarker for Response to Targeted Therapy

Mark Erlander
Trovagene



Characterization of CTCs and Other Circulating Cancer Associated Cells and their Clinical Utilities

Cha-Mei Tang
Creatv MicroTech



Session: Validation and Application of Cancer Specific Markers

Iman Jilani
Pfizer



Circulating Tumor Cells as a Biomarker in Pancreatic Cancer

James Tomlinson
University of California, Los Angeles



Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer

Keith Knutson
Vaccine & Gene Therapy Institute of Florida



NanoVelcro-Embedded Microchips for Detection and Characterization of Circulating Tumor Cells

Hsian-Rong Tseng
University of California, Los Angeles



Use of Mathematical Modeling and Large-Scale Data to Improve Biomarker Discovery Workflows

Parag Mallick
Stanford University



Development and Analytic Validation of a Next-Generation Sequencing Assay for CTCs

Allison Welsh
Foundation Medicine



Session: Clinical Utility of Circulating Nucleic Acids and CTCs

Dena Marrinucci
Epic Sciences



Epithelial-Mesenchymal Plasticity in Carcinoma Metastasis

Jing Yang
University of California San Diego, Moores Cancer Center



Session: Clinical Utility of Circulating Nucleic Acids and CTCs

John Martignetti
Icahn School of Medicine at Mount Sinai

KEYNOTE SPEAKER



Session: Reimbursement and Clinical Utility

Mark Curran
Janssen



Session: Implementation of Personalized Medicine

Aydogan Ozcan
University of California, Los Angeles

DISTINGUISHED SPEAKERS



Session: Implementation of Personalized Medicine

Sami Amr
Brigham and Women's and Massachusetts General Hospitals



Session: Implementation of Personalized Medicine

Keyur Patel
MD Anderson Cancer Center



Session: Implementation of Personalized Medicine

Hui Chen
MD Anderson Cancer Center



A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients

Antony Rapisarda
Immunexpress



Cell Free DNA in the Non-Invasive Prenatal Testing Continuum

Mathias Ehrich
Sequenom



Session: Implementation of Personalized Medicine

Mike Rosenbluth
Veracyte



Session: Reimbursement and Clinical Utility

Pramod K. Gaur
Pace University



Session: Implementation of Personalized Medicine

Sinchita Roy-Chowdhuri
MD Anderson Cancer Center



Practical Insights into the Discovery and Quantification of Immuno-Oncological Biomarkers Using Tissue Phenomics

Ralf Huss
Definiens



Session: Implementation of Personalized Medicine

Rashmi Kanagal Shamanna
MD Anderson Cancer Center



Session: Reimbursement and Clinical Utility


Michael E. Klepser
**Professor, College of Pharmacy
Ferris State University**



Clinical Next Generation Sequencing in Personalized Cancer Medicine

Rajesh Singh
MD Anderson Cancer Center

DISTINGUISHED SPEAKERS (cont.)



Fluorescence Molecular Imaging in Surgical Suites

Hisataka Kobayashi
National Cancer Institute, National Institutes of Health



Session: Application of Sequencing in the Clinical Paradigm

AmirAli Talasaz
Guardant Health



Session: Reimbursement and Clinical Utility

Elaine Lyon
ARUP Lab



Session: Multiplex Biomarker Diagnostics and Technology

Paul Tumeh
University of California, Los Angeles



Imaging in Cancer Immunology: Phenotyping of Multiple Immune Cell Subsets In-Situ in FFPE Tissue Sections

James Mansfield
PerkinElmer



Session: Implementation of Personalized Medicine

Richard Watts
QIAGEN



Session: Multiplex Biomarker Diagnostics and Technology

Rob Monroe
Veracyte



Sample Enrichment for the Detection of Ultra-Low Level Mutations in ctDNA and CTCs

Andrew Webb
EKF Molecular Diagnostics



Clinical Genomics: Blurring the Line Between Diagnosis and Discovery

Peter Nagy
Columbia University

KEYNOTE SPEAKER



Session: Reimbursement and Clinical Utility

Mark Curran
Janssen



Session: Implementation of Personalized Medicine

Aydogan Ozcan
University of California, Los Angeles

DISTINGUISHED SPEAKERS



Session: Implementation of Personalized Medicine

Sami Amr
Brigham and Women's and Massachusetts General Hospitals



Session: Reimbursement and Clinical Utility

Elaine Lyon
ARUP Lab



Session: Companion Diagnostics for Cancer and Neurodegenerative Diseases

Christopher Barnum
Emory University



Panel Discussion: Market Access for Companion Diagnostics

Scott Palmer
Ernst and Young



Panel Discussion: Market Access for Companion Diagnostics

Patrick M. Burke
Myriad



Panel Discussion: Market Access for Companion Diagnostics

Kristin Pothier
Ernst and Young



Session: Implementation of Personalized Medicine

Hui Chen
MD Anderson Cancer Center



Panel Discussion: Market Access for Companion Diagnostics

Nick Poullos
Roche Molecular Systems

Session: CDx: Present and Future



Robert Daber
Bio-Reference Laboratories



Session: Implementation of Personalized Medicine

Keyur Pravinchandra Patel
MD Anderson Cancer Center



Session: Companion Diagnostics for Cancer and Neurodegenerative Diseases

Donald L. Durden
Rady Children's Hospital, Moores Cancer Center, University of California, San Diego



Session: Implementation of Personalized Medicine

Mike Rosenbluth
Veracyte

DISTINGUISHED SPEAKERS (cont.)



Session: Reimbursement and Clinical Utility

Pramod K. Gaur
Pace University



Session: Implementation of Personalized Medicine

Sinchita Roy-Chowdhuri
MD Anderson Cancer Center



Session: Companion Diagnostics for Cancer and Neurodegenerative Diseases

Arnold Gelb
Halozyne Therapeutics



Panel Discussion: Market Access for Companion Diagnostics

Hakan Sakul
Pfizer



Session: Biomarkers in Drug Development

Francois Jean
University of British Columbia



Session: Implementation of Personalized Medicine

Rashmi Kanagal Shamanna
The University of Texas M.D. Anderson Cancer Center



Session: Biomarkers in Drug Development

David Jackson
Arno Therapeutics



Session: Implementation of Personalized Medicine

Rajesh Singh
MD Anderson Cancer Center



Session: Biomarkers in Drug Development

Andreas Jeromin
Quanterix Corporation



Session: CDx: Present and Future

Svilen Tzonev
Bio-Rad Laboratories



Session: Reimbursement and Clinical Utility

Michael E. Klepser
Ferris State University



Session: Implementation of Personalized Medicine

Richard Watts
QIAGEN

KEYNOTE SPEAKERS



Session: Reimbursement and Clinical Utility

Mark Curran
Janssen



Session: Challenges in POC Diagnostics

J. Benjamin Crocker
Massachusetts General Hospital

DISTINGUISHED SPEAKERS



Session: New and Emerging Technologies

Vadim Backman
Robert H. Lurie Comprehensive Cancer Center, Northwestern University



Session: New and Emerging Technologies

Kenneth T. Kotz
Massachusetts General Hospital and Harvard Medical School



Session: Challenges in POC Diagnostics

Keith F. Batchelder
Genomic Healthcare Strategies



Session: New Disease Areas and Global Health

Gerald Kost
UC Davis



Session: New and Emerging Technologies

Utkan Demirci
Stanford University School of Medicine



Session: Reimbursement and Clinical Utility

Elaine Lyon
ARUP Lab



Session: New and Emerging Technologies

Memed Duman
Hacettepe University



Session: New and Emerging Technologies

Euan McLeod
UCLA



Session: Reimbursement and Clinical Utility

Pramod K. Gaur
Pace University



Session: New and Emerging Technologies

Rolf Muller
Biomatrix

DISTINGUISHED SPEAKERS (cont.)



Session: Challenges in POC Diagnostics

Paul O. Gubbins
University Missouri Kansas City



Session: New and Emerging Technologies

Shashi Murthy
Northeastern University



Session: Integrating POC with Centralized Care

Donna L. Hudson
University of California San Francisco



Session: New and Emerging Technologies

Tamara Ranalli
Quidel



Session: New and Emerging Technologies

Daniel Irimia
Massachusetts General Hospital and Harvard Medical School



Session: Integrating POC with Centralized Care

James Stahl
Massachusetts General Hospital



Session: New Disease Areas and Global Health

Rahul Kashyap
Mayo Clinic



Session: Challenges in POC Diagnostics

Elizabeth Wagar
MD Anderson Cancer Center



Session: Challenges in POC Diagnostics

Donald G. Klepser
University of Nebraska Medical Center



Session: New and Emerging Technologies

Majid Ebrahimi Warkiani
University of New South Wales



Session: Reimbursement and Clinical Utility

Michael E. Klepser
Ferris State University



Session: New Disease Areas and Global Health

Bernhard H Weigl
PATH University of Washington

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:

20% until April 11, 2015

10% until May 11, 2015

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**To register online, visit: www.gtcbio.com/register/molecular-diagnostics-summit

	Commercial	Academic / Govt	Student
Molecular Diagnostics Summit	\$ 2095.00	\$ 1095.00	\$ 945.00
Individual Conference	\$ 1895.00	\$ 895.00	\$ 745.00

QUICK REGISTRATION - FAX TO (626) 466-4433

First Name: _____ Last Name: _____

Title: _____ Company: _____

Discount Coupon Code: _____

Card #: _____ Exp. Date: _____ CSV #: _____

Cardholder Name: _____

Signature: _____

Billing Address: _____

City: _____ State: _____ Zip: _____

VENUE

Hyatt Regency Mission Bay San Diego

1441 Quivira Rd

San Diego, CA 92109

(619) 224-1234

Discounted Group Rate: \$169.00 per night**Discount Deadline: May 19, 2015**Mention **GTCbio Event** to receive the group rate.

Online Reservations:

<https://resweb.passkey.com/go/GTCBiotechMolecular>

PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.